<ul>
	<li>Brinzolamide ophthalmic suspension and its metabolite are excreted predominantly by the kidney. So, it is not recommended in severe renal impaired patients.</li>
	<li>Brinzolamide ophthalmic suspension has not been studied in patients with hepatic impairment and should be used with caution in such patients.</li>
	<li>The concomitant administration of Brinzolamide ophthalmic suspension and oral carbonic anhydrase inhibitor is not recommended due to no additional benefits.</li>
	<li>If hypersensitivity reaction occurs after instillation patients should be advised to discontinue the use of Brinzolamide and consult with physicians.</li>
</ul>